Abstract
Summary
When compared in vitro with a variety of clinically useful antibiotics at concentrations that reflect therapeutic levels that can be used in vivo, actinobolin (100–250 μg/disk) strongly inhibited bacterial cultures obtained from patients with periodontitis. In vitro bacterial resistance to ampicillin, demethylchlortetracycline, or erythromycin did not confer resistance to actinobolin, and resistance to actinobolin did not confer resistance to the above indicated clinically useful antibiotics.
The advice and support of Dr. H. M. Fullmer are greatly appreciated. Thanks are extended to Mrs. Gayle Renfro and Mrs. Nancy Russell for their help in the preparation of this manuscript, and the Drs. J. H. Shaw and H. E. Grupe who kindly reviewed this paper prior to publication.
Get full access to this article
View all access options for this article.